Brazil’s Cannabis New Era Begins: ANVISA’s RDC 1,015 Takes Effect and Reshapes Latin America’s Largest Medical Market

What does this mean for the global cannabis industry?

Brazil’s medical cannabis industry entered a new chapter on May 4, 2026. After seven years under the provisional framework of RDC 327/2019, ANVISA’s comprehensive Resolution RDC 1,015/2026 officially took effect — establishing a permanent, detailed regulatory architecture for the manufacturing, importation, commercialization, prescription, and dispensation of cannabis-based pharmaceutical products across the country.

This is not a minor update. RDC 1,015 replaces the entirety of RDC 327/2019 and codifies rules that touch every participant in Brazil’s cannabis value chain: pharmaceutical manufacturers seeking Sanitary Authorization, pharmacies dispensing cannabis products, physicians and dentists writing prescriptions, international companies importing raw materials or finished products, and the 873,000+ patients who depend on medical cannabis for treatment.

The timing is strategic. RDC 1,015 is the first of ANVISA’s five landmark cannabis resolutions to take effect. The cultivation and regulatory sandbox rules (RDC 1,012, 1,013, and 1,014) follow on August 4, 2026 — meaning Brazil’s pharmaceutical cannabis framework is now live, but the domestic cultivation that will eventually feed it is still three months away.

What Changed on May 4: RDC 1,015 vs. the Old Framework

The gap between RDC 327/2019 and RDC 1,015/2026 is substantial. The old framework was deliberately provisional — designed to allow limited patient access while ANVISA gathered data. The new resolution is permanent, more permissive in patient access, and far more rigorous in manufacturing and compliance requirements.

Side-by-Side Comparison

What the Expanded Access Means for Patients

The shift from "terminal or palliative conditions" to "serious debilitating diseases" as the threshold for higher-THC products is perhaps the most impactful change for patients. Under RDC 327/2019, a patient with severe fibromyalgia, treatment-resistant epilepsy, or lupus could only access CBD-dominant products with THC capped at 0.2%. Under RDC 1,015, these patients can now be prescribed products exceeding the 0.2% THC limit — provided the prescribing physician documents the clinical rationale and obtains a signed Informed Consent Form.

Restrictions remain. Products exceeding the standard THC limit cannot be prescribed to individuals under 18, pregnant or lactating women, or patients with a history of cannabis dependence (the last requiring a documented benefit-risk assessment). All prescriptions remain limited to physicians and dentists registered with their professional councils, and the product must be specifically identified in the prescription — no generic cannabis prescriptions.

The addition of new administration routes — inhalation, buccal, sublingual, nasal, and dermatological — opens the door for product categories that simply did not exist under Brazilian regulation before. Pharmaceutical companies can now develop and seek authorization for cannabis-based topical creams, sublingual sprays, nasal preparations, and inhaled formulations. This diversification aligns Brazil with international markets like Germany, where inhalation products (particularly dried flower vaporization) have driven massive patient adoption.

How RDC 1,015 Affects Pharmacies and Dispensation

One of the most immediate practical impacts of RDC 1,015 is on Brazil’s pharmacy network. The resolution updates dispensation rules for the approximately 89,000 pharmacies and drugstores across the country.

Key Dispensation Changes

Informed Consent Form: The Termo de Consentimento Informado (TCI) remains mandatory before treatment begins. However, under RDC 1,015, the signed TCI no longer needs to be retained by the dispensing pharmacy — a reduction in administrative burden that pharmacists had lobbied for.

Prescription Control: Products with THC above 0.2% require a Yellow Receipt (Lista A3 — Receita Amarela), while products with THC at or below 0.2% require a Blue Receipt (Lista B1 — Receita Azul). These classifications were established by RDC 1,011 in February 2026 and are now the operating standard.

Compounding Pharmacies (Magistral): RDC 1,015 formally authorizes compounding pharmacies to prepare individualized CBD formulations using isolated cannabidiol with 98%+ purity. However — and this is a critical detail — this authorization is conditional on ANVISA publishing a separate regulation on Good Manufacturing Practices for magistral cannabis products. Until that norm is published, compounding pharmacies cannot begin preparation. ANVISA has not announced a timeline for this secondary regulation.

Labeling Enforcement: All cannabis products dispensed after May 4, 2026, must comply with the new labeling requirements. The terms "CBD oil," "full spectrum," "broad spectrum," and "full extract" are now prohibited on packaging. Products must carry standardized warnings stating that the product has not undergone full ANVISA efficacy and safety evaluation. Advertising to the general public remains prohibited — only technical information directed at healthcare professionals is permitted.

Import, Export, and the Path to Domestic Production

Import Authorization: A Critical Bridge

RDC 1,015 explicitly authorizes the importation of cannabis plants, extracts, CBD phytopharmaceuticals, and intermediate materials for research and pharmaceutical manufacturing within Brazil. This is a significant expansion from the previous framework, which focused primarily on finished product imports for patient access.

For international cannabis operators, this creates a clear commercial opportunity in the near term. Brazil’s 873,000+ patients currently access cannabis through three channels: 47% through personal imports under RDC 660, 31% through pharmacy products, and 22% through patient associations. The import channel remains dominant, and RDC 1,015 reinforces its legal standing while creating new import categories (raw materials for domestic manufacturing) that did not exist before.

Import and export procedures for cannabis products follow the frameworks established in RDC 988/2025 and RDC 81/2008. ANVISA’s anuência (prior authorization) requirements have been streamlined under the new framework, reducing bureaucratic delays for legitimate pharmaceutical imports.

Export: Current Restrictions and Future Trajectory

Under the current framework, export of raw cannabis plant material and seeds from Brazil is expressly prohibited (RDC 1,013, Art. 25). This prohibition applies to companies cultivating under the new authorization framework — they cannot export what they grow.

However, the regulatory trajectory points toward a future opening. RDC 1,015 establishes the pharmaceutical manufacturing framework that positions Brazilian companies to eventually produce finished cannabis pharmaceutical products — CBD isolates, standardized extracts, and formulated medications — that could be exported under pharmaceutical trade regulations once ANVISA and Brazil’s trade authorities develop the corresponding export protocols.

Brazil’s competitive advantages for future pharmaceutical cannabis exports are significant:

• Scale: 8.5 million hectares of arable land suitable for cannabis cultivation
• Climate: Tropical and subtropical zones allowing year-round outdoor and greenhouse cultivation
• Existing pharmaceutical infrastructure: Brazil is Latin America’s largest pharmaceutical market
• Research capacity: Institutions like Fiocruz, UNICAMP, and Embrapa (which launched a 12-year hemp research program in 2025) provide world-class agricultural and pharmaceutical research
• Market size: The domestic market alone is projected to reach R$1 billion in 2026 (Kaya Consulting)

For international operators watching Brazil’s cannabis market, the strategic play is clear: establish manufacturing partnerships now under RDC 1,015’s import-and-manufacture framework, position for domestic cultivation when RDC 1,013 activates in August 2026, and prepare for the eventual export opening that Brazil’s pharmaceutical capacity makes inevitable.

Brazil’s Cannabis Market: The Numbers Behind the Regulation

Understanding why ANVISA moved so decisively requires looking at the market data.

Market Growth Trajectory

Brazil is on track to surpass one million medical cannabis patients by late 2026 or early 2027. For context, Germany — widely considered the world’s fastest-growing medical cannabis market — reached approximately 900,000 patients in 13 months after its Cannabis Act took effect. Brazil has reached 873,000 patients through a more gradual, regulation-driven pathway, but with a population of 221 million (compared to Germany’s 84 million), the ceiling is far higher.

Revenue Projections

The Kaya consulting firm estimates the Brazilian medical cannabis market will reach R$1 billion (approximately US$187 million) in 2026. With domestic cultivation expected to reduce product costs by 40-60% over the next 2-3 years (patient associations already offer products at R$79-180 per bottle versus R$480-777 for imports), lower prices could simultaneously compress per-unit revenue and expand the patient base dramatically.

The projected compound annual growth rate (CAGR) through 2030 is 24.6% (Cognitive Market Research), which would place Brazil’s medical cannabis market at approximately R$2.9 billion by 2030.

What Comes Next: The August 4 Cultivation Milestone

RDC 1,015 is now live, but the most transformative elements of ANVISA’s regulatory package are still three months away.

August 4, 2026: Three Resolutions Take Effect

• RDC 1,012: Research cultivation with no THC limit for accredited institutions
• RDC 1,013: Commercial cultivation of cannabis with THC ≤ 0.3% for medicinal/pharmaceutical purposes
• RDC 1,014: Regulatory sandbox for patient associations to cultivate and prepare products

What Operators Should Do Now

1. Apply for Special Authorization (AE): Companies planning to cultivate under RDC 1,013 should begin the application process immediately, including geographic documentation, monitoring plans, and genetic sourcing for seeds or seedlings
2. Secure manufacturing partnerships: Foreign companies must partner with a Brazilian pharmaceutical entity — identifying and formalizing these partnerships before August is critical
3. Implement seed-to-sale traceability: SNGPC (National System of Controlled Product Management) integration is mandatory under the new framework; compliance systems must be operational before cultivation begins
4. Prepare for GMP compliance: ANVISA requires Good Agricultural Practices (GAP), Good Pharmaceutical Practices (GMP), and environmental compliance — the multi-agency oversight committee (ANVISA + Ministry of Justice + Ministry of Health + MAPA) will conduct inspections

The Cannabis Fair 2026: Industry Converges in São Paulo

The timing of RDC 1,015’s implementation coincides with the Cannabis Fair 2026 in São Paulo (May 21-23, Transamérica Expo Center), Latin America’s largest cannabis business gathering. The event, running alongside the Brazilian Medical Cannabis Congress, is expected to draw international operators seeking to enter Brazil’s newly regulated market. For companies evaluating Brazil as a manufacturing hub or export destination, this event represents a critical networking opportunity.

How GrowerIQ Supports Operators Entering Brazil’s Cannabis Market

Brazil’s new regulatory framework demands pharmaceutical-grade compliance from day one. SNGPC integration, batch-level traceability from seed through dispensation, Good Agricultural and Manufacturing Practice documentation, and multi-agency reporting are not optional — they are conditions of maintaining Sanitary Authorization.

GrowerIQ’s seed-to-sale platform is purpose-built for exactly this level of regulatory complexity. Operators entering Brazil’s market under ANVISA’s new framework can:

• Maintain SNGPC-ready traceability with batch-level records covering propagation, cultivation, harvest, processing, and dispensation
• Generate GMP-compliant documentation including deviation tracking, CAPA records, stability data, and quality control reports
• Track COGS across the value chain from imported raw materials through finished pharmaceutical products
• Support multi-facility operations across cultivation sites, manufacturing facilities, and distribution points
• Ensure CFR Part 11 compliant digital signatures on all quality, manufacturing, and regulatory documentation
• Automate regulatory reporting for ANVISA and the multi-agency oversight committee

As Brazil’s cannabis market scales toward R$1 billion and domestic cultivation goes live in August 2026, the companies that will succeed are those with compliance infrastructure that matches the sophistication of ANVISA’s regulatory expectations. Manual processes and spreadsheet-based tracking cannot meet the documentation demands of five interlocking resolutions, three regulatory agencies, and nearly one million patients.

Sources: ANVISA RDC 1,011-1,015/2026 (Diário Oficial da União, February 3, 2026), Licks Attorneys regulatory analysis, ELS Solutions regulatory briefing, Sechat cannabis intelligence, INCAF Cursos pharmacy dispensation analysis, Kaya Mind market data, High Times Brasil, CNN Brasil, InternationalCBC, Cognitive Market Research. Market figures reflect available reporting as of May 2026.